SCHEMBL4029614

SCHEMBL4029614

Cn1nc(-c2ccc(O)c(O)c2)c2cc(Cl)c(F)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.39
SCN9A Q15858 4/20 0.39
SCN5A Q14524 1/20 0.36
ALOX5 P09917 2/20 0.35
JAK3 P52333 1/20 0.34
APP P05067 1/20 0.33
LSS P48449 1/20 0.33
NAMPT P43490 2/20 0.33
PIK3CD O00329 2/20 0.33
ABL1 P00519 2/20 0.33
EGFR P00533 2/20 0.33
HCK P08631 2/20 0.33
SRC P12931 2/20 0.33
KDR P35968 2/20 0.33
PIK3CA P42336 2/20 0.33
PIK3CB P42338 2/20 0.33
MTOR P42345 2/20 0.33
PIK3CG P48736 2/20 0.33
EPHB4 P54760 2/20 0.33
PRKDC P78527 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4031900 0.86 ESR1 (0.43) ESR1SCN9ASCN5ALSSNAMPT
SCHEMBL4033245 0.83 ESR1 (0.44) ESR1ALOX5PIK3CDABL1EGFR
SCHEMBL4025974 0.82 ESR1 (0.47) ESR1PIK3CDABL1EGFRHCK
SCHEMBL4031930 0.81 SCN9A (0.45) ESR1SCN9ASCN5ALSSNAMPT
SCHEMBL5409059 0.81 L3MBTL1 (0.49) SCN9AL3MBTL1
SCHEMBL4025988 0.80 NAMPT (0.48) ESR1SCN9AJAK3APPNAMPT
SCHEMBL27169843 0.79 HSD17B1 (0.45) ESR1SCN9ASCN5APIK3CDABL1
SCHEMBL30791803 0.79 HSD17B1 (0.45) ESR1SCN9ASCN5APIK3CDABL1
SCHEMBL4028787 0.78 ESR1 (0.47) ESR1SRCCREBBP
SCHEMBL4032378 0.78 ESR1 (0.44) ESR1ALOX5PIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR ESR1 1028/4885SCN9A 1161/4885SCN5A 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.